Paul M Kaye
Overview
Explore the profile of Paul M Kaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
2989
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Barnett S, Roberts K, Ashwin H, Milross L, Cho J, et al.
Nat Commun
. 2025 Mar;
16(1):1979.
PMID: 40064844
The most common cause of death due to COVID-19 remains respiratory failure. Yet, our understanding of the precise cellular and molecular changes underlying lung alveolar damage is limited. Here, we...
2.
Roy M, Sengupta R, Chakraborty B, Chatterjee U, von Stebut E, Kaye P, et al.
PLoS Negl Trop Dis
. 2024 Nov;
18(11):e0012655.
PMID: 39602398
Background: Post Kala-azar Dermal Leishmaniasis (PKDL) is a dermal sequel of visceral leishmaniasis (VL), poses a significant threat to the success of ongoing kala-azar elimination program, due to its potential...
3.
Waugh M, Cyndari K, Lynch T, Koh S, Henao-Ceballos F, Oleson J, et al.
PLoS Negl Trop Dis
. 2024 Nov;
18(11):e0012363.
PMID: 39514579
Dogs represent the primary reservoir for Leishmania infantum human visceral leishmaniasis (VL) transmitted through phlebotomine sand flies. Public health initiatives targeting zoonotic VL commonly focus on dogs with severe clinical...
4.
Effects of Azithromycin on Blood Inflammatory Gene Expression and Cytokine Production in Sarcoidosis
Fraser S, Thackray-Nocera S, Wright C, Flockton R, James S, Crooks M, et al.
Lung
. 2024 Sep;
202(5):683-693.
PMID: 39284999
Introduction: In sarcoidosis granulomas, monocyte-derived macrophages are activated by pro-inflammatory cytokines including TNF and IL-6. Current drug treatment for sarcoidosis aims to suppress inflammation but disabling side effects can ensue....
5.
Younis B, Wiggins R, Khalil E, Osman M, Santoro F, Sonnati C, et al.
Mol Ther Methods Clin Dev
. 2024 Sep;
32(3):101310.
PMID: 39253357
In a recent phase 2a clinical trial, the candidate leishmaniasis vaccine ChAd63-KH was shown to be safe and immunogenic in Sudanese patients with post kala-azar dermal leishmaniasis (PKDL). However, its...
6.
Ranasinghe S, Senarathne S, Somaratne V, Lacey C, Jayakody S, Wickramasinghe A, et al.
PLoS Negl Trop Dis
. 2024 Aug;
18(8):e0012393.
PMID: 39208389
Background: Localized cutaneous leishmaniasis (LCL) is a chronic ulcerating disease. A literature review identified inconsistencies in clinical trials. The aims of this study were to reach a consensus on the...
7.
Parkash V, Ashwin H, Dey S, Sadlova J, Vojtkova B, Van Bocxlaer K, et al.
Nat Med
. 2024 Aug;
30(11):3150-3162.
PMID: 39095597
The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human...
8.
Dey N, Senaratne S, Somaratne V, Madarasinghe N, Seneviratne B, Forrester S, et al.
J Clin Invest
. 2024 Mar;
134(5).
PMID: 38426499
No abstract available.
9.
Hotez P, Bottazzi M, Kaye P, Lee B, Puchner K
Vaccine
. 2024 Feb;
41 Suppl 2:S176-S179.
PMID: 38407985
No abstract available.
10.
Milross L, Hunter B, McDonald D, Merces G, Thomson A, Hilkens C, et al.
EBioMedicine
. 2023 Dec;
99:104945.
PMID: 38142637
Background: Lung damage in severe COVID-19 is highly heterogeneous however studies with dedicated spatial distinction of discrete temporal phases of diffuse alveolar damage (DAD) and alternate lung injury patterns are...